Biogen Analysts Lower Their Forecasts After Q4 Results

Benzinga

02-13

Biogen Inc (NASDAQ:BIIB) reported better-than-expected earnings for its fourth quarter on Wednesday.

The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.

Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.

Biogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.

Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.

Biogen shares fell 4.3% to close at $133.43 on Wednesday.

These analysts made changes to their price targets on Biogen following earnings announcement.

Canaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.
Truist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.
HC Wainwright & Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.

Considering buying BIIB stock? Here’s what analysts think:

Read This Next:

Top 3 Utilities Stocks That May Collapse In Q1

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2511240528"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2511240528\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2511240528?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2511240528","market":"hk","top_or_hot":-1,"title":"Biogen Analysts Lower Their Forecasts After Q4 Results","media":"Benzinga","content":"<html><body><p><strong>Biogen Inc</strong> (NASDAQ:BIIB) reported better-than-expected earnings for its fourth quarter on Wednesday.</p>\n<p>The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.</p>\n<p>Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.</p>\n<p>Biogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.</p>\n<p>Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.</p>\n<p>Biogen shares fell 4.3% to close at $133.43 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Biogen following earnings announcement.</p>\n<ul>\n<li>Canaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.</li>\n<li>Truist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.</li>\n<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.</li>\n</ul>\n<p><strong>Considering buying BIIB stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"569\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121.png 1135w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 3 Utilities Stocks That May Collapse In Q1</strong></li>\n</ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Analysts Lower Their Forecasts After Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Analysts Lower Their Forecasts After Q4 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-02-13 22:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Biogen Inc</strong> (NASDAQ:BIIB) reported better-than-expected earnings for its fourth quarter on Wednesday.</p>\n<p>The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.</p>\n<p>Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.</p>\n<p>Biogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.</p>\n<p>Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.</p>\n<p>Biogen shares fell 4.3% to close at $133.43 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Biogen following earnings announcement.</p>\n<ul>\n<li>Canaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.</li>\n<li>Truist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.</li>\n<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.</li>\n</ul>\n<p><strong>Considering buying BIIB stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"569\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121.png 1135w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 3 Utilities Stocks That May Collapse In Q1</strong></li>\n</ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.benzinga.com/25/02/43693765/biogen-analysts-lower-their-forecasts-after-q4-results","article_id":"2511240528","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2511240528","pubTimestamp":1739455406,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"百健(Biogen)分析师在第四季度业绩公布后下调预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1},"content_text":"Biogen Inc (NASDAQ:BIIB) reported better-than-expected earnings for its fourth quarter on Wednesday.\nThe company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.\nMultiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.\nBiogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.\nRevenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.\nBiogen shares fell 4.3% to close at $133.43 on Wednesday.\nThese analysts made changes to their price targets on Biogen following earnings announcement.\n\nCanaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.\nTruist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.\nHC Wainwright & Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.\n\nConsidering buying BIIB stock? Here’s what analysts think: \n\nRead This Next: \n\nTop 3 Utilities Stocks That May Collapse In Q1","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}